The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC whose tumors express PD-L1 with a CPS of ≥1.

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for ...

Now, nivolumab -- in combination with chemotherapy -- is indicated for the first-line treatment of adults with unresectable ...

The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors ...

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

The study will be carried out in partnership with The GOG Foundation and the European Network of Gynaecological Oncological ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

A breakthrough study from Keck Medicine of USC may have found a powerful new triple therapy for glioblastoma, one of the ...

A new study found the drug kept head and neck cancers at bay for five years compared to 30 months with standard care ...

A grandad diagnosed with stage 4 lung cancer–one of the deadliest—has become disease-free after being treated with an ...

A grandad with advanced lung cancer, which often leaves patients dead within four months has become free of the disease after ...